Dermatology

This site is intended for healthcare professionals only

Login Register

MD Brand Connect
Webinars
Vaccine Hub
MDTV
Fact Check
Health Dialogues

Medical News & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry
MDTV

This site is intended for healthcare professionals only

Login Register

LoginRegister

Home
Medical news & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry

Farhat Nasim

Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at [email protected] Contact no. 011-43720751

Home

Farhat Nasim

Articles By : Farhat Nasim

Vaccine Maker to Film Maker: Serum's Adar Poonawala to invest in Karan Johar's production company

Written By Farhat Nasim21 Oct 2024 3:31 PM IST

Serene Productions has entered into a binding agreement to invest Rs 1,000 crore in production house Dharma Productions and Dharmatic Entertainment...

Indian pharma firms lag behind global peers in RnD, Patents, Publications, reveals report

Written By Farhat Nasim21 Oct 2024 2:15 PM IST

The largest disparity was observed in the number of publications per billion USD revenue, with global firms producing 8.4 times more publications than...

Allergan's Botox Cosmetic now approved for treating platysma bands

Written By Farhat Nasim21 Oct 2024 2:00 PM IST

Botox Cosmetic is the first and only product with four aesthetic indication areas: forehead lines, frown lines, crow's feet lines, and now platysma...

Sanofis Sarclisa Gets EMA Nod for Subcutaneous On-Body Injector Version

Sanofi closes deal for consumer health unit Opella: Report

Written By Farhat Nasim21 Oct 2024 1:18 PM IST

The breakthrough came after the investment group provided France with guarantees on maintaining jobs and production in the country

Merck eyes more acquisitions for life science after USD 600M Mirus Bio deal

Written By Farhat Nasim20 Oct 2024 10:15 AM IST

Merck also said it will intensify the in licensing of drug candidates in its Healthcare division.

Alkem Labs Senior Management Personnel Amit Ghare steps down

CVS Health CEO steps down amid financial challenges

Written By Farhat Nasim20 Oct 2024 9:45 AM IST

CVS cut its financial expectations for the third time in August with all major pharmacy chains attempting to navigate a drastically changed landscape

Kezar to terminate mid-stage trial for Lupus treatment

Written By Farhat Nasim20 Oct 2024 9:30 AM IST

The regulator's decision came after the company paused the study in September to review safety data following the deaths of four patients.

Torrent Pharma Slapped with Rs 41.33 Crore GST Penalty for Alleged Erroneous Export Refunds

NPPA slaps over Rs 6L demand notice to Torrent Pharma

Written By Farhat Nasim19 Oct 2024 3:32 PM IST

The demand notice is for the launch of a new drug wherein price approval was taken after the launch, Torrent Pharma said in a regulatory filing.

Gland Pharma names Shyamakant Giri as new CEO

Written By Farhat Nasim19 Oct 2024 3:29 PM IST

New Delhi: Gland Pharma has announced a major leadership change with the appointment of Shyamakant Giri as the new Chief Executive Officer (CEO),...

Merck's RSV antibody Clesrovimab for infants shows 60.4% effectiveness in mid-to-late stage clinical trial

Written By Farhat Nasim19 Oct 2024 12:15 PM IST

The drug clesrovimab also helped reduce RSV associated hospitalizations by 84.2% compared to placebo, Merck said.

Block Novo Holdings' USD16.5B Catalent acquisition: Consumer Groups Urge FTC over antitrust concerns

Written By Farhat Nasim19 Oct 2024 11:30 AM IST

The deal could constrain options for competitors such as Amgen, Pfizer, Roche, and AstraZeneca , who are reportedly developing their own GLP 1 drugs.

Sage Therapeutics reshuffles leadership, cuts 165 jobs to focus on postpartum depression drug launch

Written By Farhat Nasim19 Oct 2024 10:30 AM IST

The drugmaker plans to prioritize the launch of its postpartum depression pill Zurzuvae, that has been jointly developed with Biogen.

Powered By: Hocalwire

X

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok